Abstract 247P
Background
Evaluate Role of ADC values in assessing response to chemoradiotherapy in cervix cancer & contribution of contrast MRI to identify residual disease, post-treatment completion.
Methods
Prospective observational study in 100 patients of histopathologically proven cancer of the uterine cervix. Based on clinical outcome integrating final histopathological diagnosis patients were classified as either complete response or Residual disease. Validity & reliability of PET-CT, Contrast MRI, and ADC values were checked by calculating sensitivity, specificity, PPV & NPV.
Results
Residual lesions have significantly lower ADC value than that of post-treatment changes. Mean ADC values of residual tumors: 1.26±0.238 x 10-3 mm2/s and mean ADC values of lesions due to post-treatment changes: 1.540 ±0.218 x 10-3 mm2/s (statistically significant difference in between malignant and post-treatment lesions p < 0.05). ADC sensitivity 67%, specificity 83%, PPV 35%, NPV 95 % and accuracy 81% in differentiating residual disease from post-treatment changes. PPV, NPV, sensitivity, and specificity with PET-CT was 93%, 89%, 98%, and 73%. PPV, NPV, sensitivity, and specificity of contrast MRI was 16%, 91%, 58%, and 59%.
Conclusions
Diffusion imaging differentiates residual cervix malignancies from post-treatment changes based on ADC values and can be a promising and evocative biomarker. Complimentary use of ADC and PET/CT may increase diagnostic confidence. However, the cost and logistics of MRI imaging is an important factor in routine clinical implementation especially in developing countries like India, where carcinoma cervix is associated with poor socioeconomic status.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Rajiv Gandhi cancer Institute and Research Centre, New Delhi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
314P - An EGF motif of Del1 inhibits efficient angiogenesis and suppresses tumour growth in vivo
Presenter: Hisataka Kitano
Session: Poster display session
Resources:
Abstract
315P - Inhibition of JAK1 sensitizes human head and neck cancer cells to cetuximab
Presenter: James Bonner
Session: Poster display session
Resources:
Abstract
316TiP - Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study
Presenter: Ezra Cohen
Session: Poster display session
Resources:
Abstract
322P - Three-year overall survival update from the PACIFIC trial
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract
323P - Novel tumour mutation score versus tumour mutation burden in predicting survival after immunotherapy in pan-cancer from MSK-IMPACT cohort
Presenter: Yuan Li
Session: Poster display session
Resources:
Abstract
324P - A novel anti-PD-1 antibody HLX10 study led to the initiation of combination immunotherapy
Presenter: Tsu Yi Chao
Session: Poster display session
Resources:
Abstract
325P - Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma
Presenter: Lawrence Wong
Session: Poster display session
Resources:
Abstract
326P - Autologous V gamma 9 V delta 2 T cell therapy to target Epstein Barr Virus (EBV)-related malignancies
Presenter: Esdy Rozali
Session: Poster display session
Resources:
Abstract
327P - Neoantigen profile of hepatocellular carcinoma reveals its correlation with tumour progression and clonal evolution
Presenter: Xiaolong Liu
Session: Poster display session
Resources:
Abstract
328P - A retrospective analysis of patients with non-small cell lung cancer who developed drug-induced lung disorder by immune checkpoint inhibitors
Presenter: Fumiko Hayashi
Session: Poster display session
Resources:
Abstract